Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ann Oncol. 2009 Jun;20(6):1080-5. doi: 10.1093/annonc/mdn751. Epub 2009 Feb 23.

Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment.

Author information

  • 1Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Abstract

BACKGROUND:

Hepatosplenic T-cell lymphoma (HSTCL) is a rare peripheral T-cell lymphoma; treatment with standard anthracycline-containing chemotherapy regimens has been disappointing, and an optimal treatment strategy for this patient population has not yet been determined.

METHODS:

We identified 15 cases of pathologically confirmed HSTCL in the institution's database. Clinical characteristics and treatment results were reviewed.

RESULTS:

Complete responses (CRs) were achieved in 7 of 14 patients who received chemotherapy. Achievement of CR was followed by hematopoietic stem-cell transplantation in three patients. Median duration of CR was 8 months (range 2 to 32+ months) with four patients currently alive and in CR at 5, 8, 12, and 32 months, respectively. Median overall survival (OS) was 11 months (range 2 to 36+ months). Patients who achieved a CR had a median OS of 13 months, compared with 7.5 months in patients who did not achieve a CR. Risk factors associated with worse outcome included male gender, failure to achieve a CR, history of immunocompromise, and absence of a T-cell receptor gene rearrangement in the gamma chain.

CONCLUSION:

A better understanding of the pathophysiology of HSTCL and new therapeutic strategies are needed.

PMID:
19237479
[PubMed - indexed for MEDLINE]
PMCID:
PMC4092251
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk